Target's General Information
Target ID T18779
Target Name Mucin-1 (MUC1)
Synonyms Tumour-associated antigen mucin 1; Tumor-associated mucin; Tumor-associated epithelial membraneantigen; Tumor-associated epithelial membrane antigen; Polymorphic epithelial mucin; Peanut-reactive urinary mucin; PUM; PEMT; PEM; MUC-1; Krebs von den Lungen-6; KL-6; H23AG; Episialin; EMA; Carcinoma-associated mucin; Cancer antigen 15-3; CD227 antigen; CD227; CA 15-3; Breast carcinoma-associated antigen DF3
Target Type Clinical trial
Gene Name MUC1
UniProt ID MUC1_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Bipolar disorder
Example drug TG-4010 Phase 2/3 [1], [2], [3]
Tissue Pre-frontal cortex
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.07
Z-score: -0.41
P-value: 4.59E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Breast cancer
Example drug AS-1402 Phase 2 [2], [3], [4]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.61
Z-score: 1.37
P-value: 1.85E-53
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 1.9
Z-score: 1.19
P-value: 9.93E-08
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Example drug Emepepimut-S Phase 2 [2], [3], [5]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.72
Z-score: -1.38
P-value: 6.28E-51
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.39
Z-score: -0.41
P-value: 1.41E-10
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Rectal cancer
Example drug MUC1-Poly-ICLC Phase 2 [2], [3], [6]
Tissue Rectal colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.43
Z-score: -0.83
P-value: 1.61E-01
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.11
Z-score: -0.27
P-value: 1.77E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Myeloma
Example drug ImMucin Phase 1/2 [2], [3], [7]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.33
Z-score: -1.54
P-value: 1.53E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Acute myelocytic leukemia
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.2
Z-score: 0.38
P-value: 2.90E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
REF 5 ClinicalTrials.gov (NCT00828009) BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell LungCancer That Cannot Be Removed by Surgery. U.S. National Institutes of Health.
REF 6 ClinicalTrials.gov (NCT00773097) Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma. U.S. National Institutes of Health.
REF 7 ClinicalTrials.gov (NCT01232712) A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.